CTLA4 and neoplasm: Perez‐Ruiz et al. recently reported that the prophylactic use of TNF inhibitors concomitant with combined anti‐CTLA‐4 and anti‐PD‐1 therapy in mouse models ameliorated irAEs and also improved anti‐tumor efficacy.33 It is therefore important to understand the role of TNF inhibitors in tumor immunotherapy.